retatrutide type 2 diabetes phase 2 results 2024 ESC 2024: improves lipid and cardiovascular risk profile in II trial Effects of retatrutide, dulaglutide, and

In clinical trials, tesamorelin reduced visceral adipose tissue by approximately 15% over 26 weeks, without significantly altering subcutaneous fat

No med fixes chronic sleep deprivation

Curr Opin Endocrinol Diabetes Obes 5(4):252255 Sun EW, Martin AM, Wattchow DA et al (2019) Metformin triggers PYY secretion in human gut mucosa

It has impacted so many events of my life

Because these medications suppress appetite, athletes who take them are susceptible to a condition called RED-S, or Relative Energy Deficiency in Sport. Basically, this is when your exercise output consistently outpaces caloric intake

For the management of obesity, NICE guideline NG246 (2023) recommends a stepped approach beginning with lifestyle interventions, followed by pharmacological treatment where appropriate